spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Rituximab 

 HSMN NewsFeed - 31 Jan 2025
U.S. FDA Approves Celltrion's AVTOZMA(R) (tocilizumab-anoh), a Biosimilar to ACTEMRA(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Apr 2024
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Jan 2020
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Nov 2018
AbbVie Receives European Commission Approval of VENCLYXTO(R) (venetoclax) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Jun 2018
MEI Pharma Presents Clinical Data on ME-401 at the European Hematology Association Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
Biopharmaceuticals Generics Licensing
 HSMN NewsFeed - 5 Mar 2018
Aridis Pharmaceuticals, Inc. Appoints Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer, and Mitchell H. Rosner, Ph.D. as Vice President of Quality
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Mar 2016
ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2016
Forty Seven Inc. Completes $75M Series A Financing and Licenses Technology from Stanford University to Advance Next Generation Immuno-Oncology Programs
Biopharmaceuticals Oncology Venture Capital Licensing
 HSMN NewsFeed - 28 Jan 2016
Venetoclax Receives 3rd Breakthrough Therapy Designation from the FDA for the Combination Treatment of Patients with Untreated Acute Myeloid Leukemia not Eligible for Standard Induction Chemotherapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2015
Hetero Announces the Launch of Biosimilar Rituximab (MABALL(TM)) in India
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 20 Feb 2015
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Jul 2014
Celldex Therapeutics Announces Senior Leadership Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Sep 2013
Cimzia(R) (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2013
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 3 Jul 2013
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Feb 2013
ARIAD Announces Appointment of European General Manager and Other Key Members of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Feb 2013
Biogen Idec to Acquire Full Rights and Control of TYSABRI(R) from Elan for Upfront Cash and Contingent Payments
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2012
Epizyme Announces Appointment of Eric Hedrick, M.D., as Chief Medical Officer
Biopharmaceuticals Personalized Medicine Personnel
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Spectrum Pharmaceuticals to Develop Biosimilar Rituximab
Biopharmaceuticals Oncology Generics
 HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Jun 2010
Trubion Pharmaceuticals Wins Genentech and Biogen Idec Patent Appeal
Biopharmaceuticals Litigation
 HSMN NewsFeed - 24 May 2010
Seattle Genetics Names Vice President, Sales and Announces Management Promotion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jul 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., To Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 May 2009
UCB's CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2008
Monoclonal Antibody Sales to Almost Double in Coming Years
Biopharmaceuticals
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Biogen Idec Names Hans Peter Hasler Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 May 2008
Biogen Idec Celebrates 30 Years of Transforming Discovery into Care
Biopharmaceuticals
 HSMN NewsFeed - 15 May 2008
Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2007
Updated REVLIMID(R) Clinical Results Presented at the 12th International Workshop on Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 12 Jul 2007
Point Therapeutics Update
Biopharmaceuticals
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Genentech Provides Update on Pipeline Agents at the American Society of Clinical Oncology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Point Therapeutics Reduces Costs by Cutting Work Force
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Apr 2007
Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Feb 2007
Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Feb 2007
Roche Continues to Strengthen Research and Development
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Point Therapeutics Announces Resignation of William Whelan from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2007
Genentech Announces Senior Vice President and Vice President Promotions in Commercial, Legal and Product Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jan 2007
Point Therapeutics Provides Preliminary Results from Phase 2 Metastatic Pancreatic Cancer Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2006
FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2006
Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2006
Phase III Study of Avastin(R) in Advanced Pancreatic Cancer Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 1 Jun 2006
Point Therapeutics Receives Fast Track Designation for Talabostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 May 2006
Genentech Submits Supplemental Biologics License Application for Avastin With Chemotherapy in First-Line Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 May 2006
Celldex appoints Thomas Davis, M.D as Chief Medical Officer and Tibor Keler, Ph.D as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2006
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at Over Nine Years Follow-Up To Be Presented
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 May 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
Immunomedics and UCB Announce Worldwide Development Collaboration and License Agreement for Epratuzumab
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 176

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 176 additional stories matching:
Rituximab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.